Unknown

Dataset Information

0

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.


ABSTRACT: Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow Transplantation (EBMT), Supportive Care Committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies. With these recommendations, we address emerging toxicity mitigation strategies, we advocate for the characterization of baseline organ function according to age and discipline-specific criteria, we recommend early critical care assessment when indicated, with consideration of reversibility of underlying pathology (instead of organ failure scores) to guide critical care interventions, and we call for researchers, regulatory agencies and sponsors to support and facilitate early inclusion of young patients with cancer in well-designed clinical trials.

SUBMITTER: Ragoonanan D 

PROVIDER: S-EPMC9393856 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.

Ragoonanan Dristhi D   Khazal Sajad J SJ   Abdel-Azim Hisham H   McCall David D   Cuglievan Branko B   Tambaro Francesco Paolo FP   Ahmad Ali Haider AH   Rowan Courtney M CM   Gutierrez Cristina C   Schadler Keri K   Li Shulin S   Di Nardo Matteo M   Chi Linda L   Gulbis Alison M AM   Shoberu Basirat B   Mireles Maria E ME   McArthur Jennifer J   Kapoor Neena N   Miller Jeffrey J   Fitzgerald Julie C JC   Tewari Priti P   Petropoulos Demetrios D   Gill Jonathan B JB   Duncan Christine N CN   Lehmann Leslie E LE   Hingorani Sangeeta S   Angelo Joseph R JR   Swinford Rita D RD   Steiner Marie E ME   Hernandez Tejada Fiorela N FN   Martin Paul L PL   Auletta Jeffery J   Choi Sung Won SW   Bajwa Rajinder R   Dailey Garnes Natalie N   Kebriaei Partow P   Rezvani Katayoun K   Wierda William G WG   Neelapu Sattva S SS   Shpall Elizabeth J EJ   Corbacioglu Selim S   Mahadeo Kris M KM  

Nature reviews. Clinical oncology 20210219 7


Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-cell therapies, including chimeric antigen receptor (CAR)-expressing cells, and other immunotherapies, such as immune-checkpoint inhibitors, is increasing. In this Consensus Statement, members of the Pediatric Acute Lung Injury and Sepsis Investigators (  ...[more]

Similar Datasets

| S-EPMC5624597 | biostudies-other
| S-EPMC8753211 | biostudies-literature
| S-EPMC9350252 | biostudies-literature
| S-EPMC4744260 | biostudies-other
| S-EPMC6855930 | biostudies-literature
| S-EPMC11365006 | biostudies-literature
| S-EPMC10905233 | biostudies-literature
| S-EPMC4874574 | biostudies-literature
| S-EPMC3795593 | biostudies-literature
| S-EPMC10279651 | biostudies-literature